A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04115956|
Recruitment Status : Recruiting
First Posted : October 4, 2019
Last Update Posted : August 11, 2020
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2.
In both phases, treatment of each individual participant will continue for up to 8 cycles or until any stopping events occur.
Approximately 46 participants will be enrolled.
|Condition or disease||Intervention/treatment||Phase|
|AL Amyloidosis||Drug: Melphalan-Flufenamide (Melflufen) Drug: Dexamethasone||Phase 1 Phase 2|
This is a clinical trial of melphalan flufenamide (melflufen), a peptide-conjugated alkylator which belongs to an novel class of drugs called peptidase-enhanced compounds, and targets the transformation process of tumor cells with a unique mechanism of action, as potential treatment option of AL amyloidosis.
AL amyloidosis is a rare progressive disease caused by proteotoxic light chain protein produced by small plasma cell clone. This plasma cell dyscrasia is characterized by monoclonal plasma cell's excessive production of monoclonal immunoglobulin light-chains that tends to misfold and subsequently deposit as amyloid fibrils in visceral organs. The plasma cell dyscrasia in AL amyloidosis is similar to that in multiple myeloma (MM) and therapies that are effective in MM are often used to treat AL amyloidosis.
Melphalan flufenamide is currently been evaluated in several ongoing clinical trials in patients with multiple myeloma, with observed efficacy. There are currently no therapies approved for treatment of AL amyloidosis and based on the efficacy of melphalan flufenamide and the demonstrated efficacy of melphalan (and other alkylators), it is anticipated that patients with AL amyloidosis may receive benefit from treatment with melphalan flufenamide.
This study consist of a screening period (up to 28 days), a treatment period (up to 8 cycles) and a follow-up period (up to 24 months).
Phase 1: Approximately 8-30 participants will be screened to achieve 7-23 enrolled participants.
Phase 2: Approximately 30 participants will be screened to achieve 23 enrolled participants.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Melflufen + Dexamethasone|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy|
|Actual Study Start Date :||August 6, 2020|
|Estimated Primary Completion Date :||February 2023|
|Estimated Study Completion Date :||April 2024|
Experimental: Melflufen and dexamethasone in combination
Intravenous infusion of melflufen Day 1 of 28 day cycles, in combination of dexamethasone on Days 1 and 2 of each 28-day cycle.
Drug: Melphalan-Flufenamide (Melflufen)
Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
Other Name: Dexamethason JENAPHARM
- The primary objective in Phase 1 is to explore safety and tolerability of melflufen [ Time Frame: During phase 1 for up to 8 cycles of treatment of 28 days each (approx. up to 8 months) ]
- Frequency and grade of Adverse Events. The maximum grade for each type of AE will be recorded for each participant and frequency tables will be presented and reviewed to determine patterns
- Laboratory values (laboratory abnormalities) for hematology, coagulation, blood chemistry, urinalysis
- The primary objective in Phase 1 is to identify recommended Phase 2 dose (RP2D) [ Time Frame: During phase 1 for up to 8 cycles of 28 days each (approx. up to 8 months) ]Endpoint: Dose-Limiting Toxicity (DLT) during Cycle 1 up to maximum dose of melflufen of 40 mg. A DLT event is defined as thrombocytopenia, neutropenia, non-hematologic toxicity and/or inability to receive Cycle 2 Day 1 dose within 14 days from planned Cycle 2 Day 2 due to continued melflufen-related toxicity from Cycle 1.
- The primary endpoint in Phase 2 is to evaluate the hematologic overall response rate (ORR) after 4 cycles at the RP2D determined in Phase 1 [ Time Frame: During phase 2 after 4 cycles of treatment ( approx. 4 months) ]The proportion of participants who achieve a hematologic Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR)
- To assess pharmacokinetic profile of melflufen in this patient population [ Time Frame: At Cycle 1 Day 1 and Cycle 2 Day 1 at time points 5-10 minutes, 1-2 hours and 3-8 hours after end of infusion. Each cycle length is 28 days. ]Melphalan plasma concentration post melflufen administration at 3 time points
- To assess best hematologic response [ Time Frame: Throughout the study treatment of up to 8 cycles of 28 days each (approx. 8 months) per patient ]Proportion of patients with each outcome (Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), No Response (NR) or Progressive Disease (PD))
- To assess the duration of hematologic response [ Time Frame: Throughout the study treatment period of up to 8 cycles of 28 days each (approx 8 months) per patient ]Median time (Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), No Response (NR) or Progressive Disease (PD))
- To assess the proportion of organ system responses [ Time Frame: Throughout the study treatment period of up to 8 cycles of 28 days each (approx 8 months) per patient ]Proportion of participants with kidney, cardiac or liver response, respectively
- To assess duration of organ system responses [ Time Frame: Throughout the study treatment period of up to 8 cycles (approx 8 months) per patient ]Duration of organ responses separately for each organ
- To assess hematologic ORR (overall response rate) [ Time Frame: During phase 1 for up to 8 cycles of treatment of 28 days each (approx. up to 8 months) ]Proportion of participants who achieve a hematologic CR, VGPR or PR
- To assess time to next AL amyloidosis treatment [ Time Frame: Throughout the study, covering up to 8 cycles (approx. 8 months) of treatment and 24 months of follow up ]Time to next AL amyloidosis treatment
- To assess Overall Survival (OS) [ Time Frame: Throughout the study, covering up to 8 cycles (approx. 8 months) of treatment and up to 24 months of follow up ]Overall survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04115956
|Contact: Head of Clinical Development||+46 8 615 20 firstname.lastname@example.org|
|Contact: Clinical Operations Director||+46 8 615 20 email@example.com|
|United States, Massachusetts|
|Boston University Medical Center||Not yet recruiting|
|Boston, Massachusetts, United States, 02111|
|Principal Investigator: Vaishali Sanchorawala, MD|
|Fakultní Nemocnice Ostrava||Not yet recruiting|
|Ostrava - Poruba, Czechia, 70852|
|Principal Investigator: Roman Hájek, MD|
|Centre Hospitalier Universitaire de Limoges||Not yet recruiting|
|Limoges, France, 87000|
|Principal Investigator: Arnaud Jaccard, MD|
|Universitätsklinikum Heidelberg||Not yet recruiting|
|Heidelberg, Germany, 69120|
|Principal Investigator: Stefan Schönland, MD|
|Alexandra General Hospital of Athens||Not yet recruiting|
|Athen, Greece, 11528|
|Principal Investigator: Efstathios Kastritis, MD|
|Hadassah University Hospital Ein Kerem||Not yet recruiting|
|Jerusalem, Israel, 9112001|
|Principal Investigator: Moshe Gatt, MD|
|Fondazione IRCCS Policlinico San Matteo||Not yet recruiting|
|Pavia, Italy, 27100|
|Principal Investigator: Giovanni Palladini, MD|
|Oslo University Hospital - Rikshospitalet||Recruiting|
|Oslo, Norway, 0372|
|Principal Investigator: Fredrik Schjesvold, MD|
|Instytut Hematologii i Transfuzjologii||Not yet recruiting|
|Warszawa, Poland, 00791|
|Principal Investigator: Krzysztof Jamroziak, MD|
|Hospital Clinic de Barcelona||Recruiting|
|Barcelona, Spain, 08036|
|Principal Investigator: Maria Teresa Cibeira, MD|
|University College London Hospitals NHS Foundation Trust||Not yet recruiting|
|London, United Kingdom, NW1 2BU|
|Principal Investigator: Ashutosh Wechalekar, MD|
|Principal Investigator:||Giovanni Palladini, MD||University Hospital San Matteo in Pavia|